Dr. Lucky Krishnia’s Post

Rachel Watkins is Director of Experimental Biology at CoSyne Therapeutics, a company working on creating a platform for drug discovery in under-served brain diseases, based on high-quality scientific data integrated with AI and machine learning. We all know the saying ‘garbage in, garbage out’ so CoSyne have concentrated on generating the highest quality, clinically relevant data for their platform. Focusing initially on astroglial diseases, including aggressive brain cancers, CoSyne aim to develop a model that can aid drug discovery for brain diseases and beyond. Working from a biobank of patient-derived tumour cell lines, cells are grown in 3D culture to mimic tumour conditions as closely as possible e.g. hypoxia gradient. These cells are then characterised through whole-genome sequencing, single-cell transcriptomics and CRISPRi screens and these data used to power AI generated cellular simulations in order to identify biomarker / target pairings. To verify their platform’s efficiency CoSyne have identified biomarker/target pairings already established in the literature as well as many novel targets. This work has shown that the platform is working well and CoSyne are currently looking at re-purposing phase I safe but de-prioritised therapeutics towards new indications to accelerate the path of new treatments for patients in need. Rachel will be speaking at Drug Discovery 2024 on Thursday 3 October in the track ‘Target discovery and disease modelling’. Register now to catch her talk at Drug Discovery 2024: https://lnkd.in/ePmtmfN9 #braincancer #CRISPR #braindisease #singlecellsequencing #singlecell #therapeutics #cancer #tumor #braintumor #genomics #wholegenomesequencing #transcriptomics

I am excited to share that our research on “Network Dynamics and Therapeutic Aspects of mRNA and Protein Markers within the Recurrence Sites of Pancreatic Cancer,” guided by Dr. Animesh Acharjee (Assistant Professor, University of Birmingham) has been published in the multidisciplinary (Q1) journal, #Heliyon  Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a high mortality rate and challenging diagnosis. Our study aimed to identify genes, proteins, and clinical parameters to uncover stable molecular associations across multiple #PDAC recurrences that could be used as therapeutic tools in the future. We employed #statistical methods such as Spearman partial correlation analysis, univariate analysis, dimension reduction (PLS), machine learning techniques, and network construction to achieve these findings. I am immensely grateful to all my mentors and team members for this research project. As I look forward to new research opportunities, I am eager to explore further collaborations in this impactful field. I appreciate your support and look forward to connecting with others who are passionate about advancing cancer research. I would highly appreciate your referrals and recommendations. #CancerResearch #PancreaticCancer #Machinelearning #Proteomics #Multiomics #Cancertherapeutics #Metabolomics #Bioinformatics #ScientificJournals #ResearchOpportunities #NetworkDynamics #OpenToWork #CareerOpportunities #HelpingHand #Researchscientists

MECO Diagnostics & UGenome Case study | bone metastasis risk in breast cancer treatment Background. - Fibrotic-like matrix stiffness pro- motes distinct metastatic phenotypes in cancer cells, which are preserved after transition to softer microen- vironments, such as bone marrow. - Using differential gene expression analysis a score of mechanical conditioning (MeCo) associated with bone metastasis in patients with breast cancer. Watson, A. W., Grant, et al. (2021). Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell reports. UGenome's service - Client had access to RNA-seq data from breast cancer patients before treatment with Nintenab* - UGenome pre-processed and aligned the RNA-seq data to a reference genome. - UGenome converted the aligned RNA-seq data to transcripts per million and calculated a MeCo score for each patient. *Nintedanib is used to treat idiopathic pulmonary fibrosis #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics, #science, #dna, #research, #genomics, #medicine, #immunology, #drugdiscovery, #datascience, #lifesciences, #biostatistics, #health, #pharma, #genomeannotation, #pharmacogenomics, #pharmacogenetics, #genomicmedicine, #sequencing, #dataanalysis, #machinelearning, #precisionmedicine, #metagenomics,

MECO Diagnostics & UGenome Case study | bone metastasis risk in breast cancer treatment Background. - Fibrotic-like matrix stiffness pro- motes distinct metastatic phenotypes in cancer cells, which are preserved after transition to softer microen- vironments, such as bone marrow. - Using differential gene expression analysis a score of mechanical conditioning (MeCo) associated with bone metastasis in patients with breast cancer. Watson, A. W., Grant, et al. (2021). Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell reports. UGenome's service - Client had access to RNA-seq data from breast cancer patients before treatment with Nintenab* - UGenome pre-processed and aligned the RNA-seq data to a reference genome. - UGenome converted the aligned RNA-seq data to transcripts per million and calculated a MeCo score for each patient. *Nintedanib is used to treat idiopathic pulmonary fibrosis #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics, #science, #dna, #research, #genomics, #medicine, #immunology, #drugdiscovery, #datascience, #lifesciences, #biostatistics, #health, #pharma, #genomeannotation, #pharmacogenomics, #pharmacogenetics, #genomicmedicine, #sequencing, #dataanalysis, #machinelearning, #precisionmedicine, #metagenomics,

Breakthrough in Cancer Research: Manipur Team Patents New Anticancer Composition Researchers from Manipur University and the Institute of Bioresources and Sustainable Development have developed a groundbreaking anticancer composition, earning them Patent No. 540410. Led by Dr. Thiyam Ramsing Singh, Prof. Lisam Shanjukumar Singh, Dr. Ch. Brajakishor Singh, and Dr. Thangjam Davis Singh, the team created a treatment that enhances the efficacy of cisplatin, a common chemotherapeutic agent. Cisplatin often causes relapse and resistance, limiting its use due to severe toxicity. The team extracted planispine A from Zanthoxylum armatum DC., which, when combined with cisplatin, improves its effectiveness by 5.5 times and makes cancer cells more susceptible. This synergy inhibits the DNA repair pathway for cisplatin-induced interstrand DNA cross-links. Their discovery offers new hope for cancer treatments, potentially leading to more effective therapies with reduced side effects, marking a significant milestone in cancer biology. Follow us at IPQuad Partners Advocate Apoorva Sharma Urvashi Sharma Adv. Jaspreet Singh Piyush Yadav Kartik Mogha Aditya Singh Aditi Sharma Parminder Kaur Praveen Yadav Priyanjal Jain Deepanshu Mandwal Madhusudan Prasad RITIKA TAPARIA Sk Badsha SK SOHEL Ayushman Banwariya #CancerResearch #ManipurUniversity #Anticancer #NewTreatment #MedicalBreakthrough #Chemotherapy #Cisplatin #DrugResistance #PlanispineA #CancerBiology #InnovativeMedicine #HealthInnovation #ResearchAndDevelopment #Patent #CancerTreatment #MedicalScience #ChemotherapeuticEfficacy #DNARepairInhibition #Rutaceae #ZanthoxylumArmatum #CancerTherapy #ChemoPrevention #Biotechnology #CancerCells #MedicalInnovation #Oncology #HealthResearch #ScientificBreakthrough #MedicalDiscovery #Pharmacology #CancerHope

MECO Diagnostics & UGenome Case study | bone metastasis risk in breast cancer treatment Background. - Fibrotic-like matrix stiffness pro- motes distinct metastatic phenotypes in cancer cells, which are preserved after transition to softer microen- vironments, such as bone marrow. - Using differential gene expression analysis a score of mechanical conditioning (MeCo) associated with bone metastasis in patients with breast cancer. Watson, A. W., Grant, et al. (2021). Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell reports. UGenome's service - Client had access to RNA-seq data from breast cancer patients before treatment with Nintenab* - UGenome pre-processed and aligned the RNA-seq data to a reference genome. - UGenome converted the aligned RNA-seq data to transcripts per million and calculated a MeCo score for each patient. *Nintedanib is used to treat idiopathic pulmonary fibrosis #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics, #science, #dna, #research, #genomics, #medicine, #immunology, #drugdiscovery, #datascience, #lifesciences, #biostatistics, #health, #pharma, #genomeannotation, #pharmacogenomics, #pharmacogenetics, #genomicmedicine, #sequencing, #dataanalysis, #machinelearning, #precisionmedicine, #metagenomics,

Dovetail Genomics debuts LinkPrep™ NGS technology at the AACR Annual Meeting, showcasing its potential for revolutionizing cancer research. This innovative chromatin conformation approach promises enhanced sensitivity in detecting structural variants and chromatin topology features, providing a holistic view of genetics, epigenetics, and chromatin conformation in cancer progression. Mathew Easterday, Ph.D., J.D., CEO of Cantata Bio, emphasized the groundbreaking potential of LinkPrep™ technology, highlighting its ability to bridge the gap in detecting clinically relevant cancer driver mutations. With its exceptional sensitivity, uniform coverage, and rapid workflow, LinkPrep™ chemistry emerges as the optimal solution for identifying these variants, ultimately enhancing the discovery and annotation of novel drivers and mechanisms of cancer. Currently undergoing late-stage validation, Dovetail Genomics actively seeks strategic partnerships to further demonstrate the clinical utility of LinkPrep™ technology across specific cancer indications. By capturing genetic variation within the context of the 3D genome, LinkPrep™ enables simultaneous genetic and epigenetic data analyses, offering insights into allele-resolved copy number variation, haplotype resolution of variant co-occurrence, and karyotype reconstruction in the context of a cancer genome. With its compatibility with off-the-shelf or user-defined hybrid capture panels, LinkPrep™ technology promises improved sensitivity over whole-genome approaches, paving the way for advancements in cancer research and therapeutic strategies. #ngstechnology #cancerresearch #chromatinconformation #genetics #epigenetics #structuralvariants #clinicalutility #biotechnology #innovation #precisionmedicine

#AMCDiscoveries Solitary fibrous tumor/Hemangiopericytoma (SFT/HPC) is a rare subtype of soft tissue sarcoma harboring NAB2-STAT6 gene fusions. Mechanistic studies and therapeutic development on SFT/HPC are impeded by scarcity and lack of system models. Researchers from National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School conducted a study, to establish and characterise a novel SFT/HPC patient-derived cell line (PDC), SFT-S1, and screen for potential drug candidates that could be repurposed for the treatment of SFT/HPC. In their study, they established a novel PDC model of SFT/HPC with comprehensive characterization of its genomic, epigenomic and transcriptomic landscape, which can facilitate future preclinical studies of SFT/HPC, such as in vitro drug screening and in vivo drug testing. “Through this work we have made a small step in the understanding of Rare Cancers, an important disease area not to be ignored”, said Asst Prof Chan Yong Sheng Jason, Consultant, Division of Medical Oncology, NCCS. Read more in Human Cell, SpringerLink: https://bit.ly/3RYNQYp AMC researchers involved: Jing Yi Lee, Abner Lim, Zexi Guo, Li Zhimei (NCCS), Jessica Sook Ting Kok, Elizabeth Chun Yong Lee, Lim Boon Yee (Bonnie), Bavani Kannan, Jui Wan Loh, Cedric Ng, Kah Suan Lim, Bin Tean Teh, Tun Kiat Ko, Jason Yongsheng Chan, MBBS-PhD #AMRInews #research #Singapore #biomedical #epigenomics #rarecancers #nextgenerationsequencing #NCCS #DukeNUS #SingHealth #AMC Visit SingHealth Duke-NUS AM Research Institute (AMRI) at bit.ly/aboutAMRI

🌟 Exciting News! 🌟 I'm thrilled to share that my article titled "Targeting PERK and GRP78 in Colorectal Cancer: Genetic Insights and Novel Therapeutic Approaches" has been published in the esteemed European Journal of Pharmacology (Q1)! 🎉 In this study, we explored the critical role of the unfolded protein response (UPR) in colorectal cancer (CRC), which remains one of the leading causes of cancer-related deaths globally. We hypothesized that genetic variants in endoplasmic reticulum (ER) stress response genes, specifically PERK and GRP78, impact CRC susceptibility. Through a comprehensive analysis involving 64 CRC patients and a control group, we confirmed significant differences in the expression of these genes between cancerous and normal tissues. Our findings also revealed correlations between specific genotypes of PERK and GRP78 and CRC risk, opening up promising avenues for diagnosis and treatment. I want to express my heartfelt gratitude to all the professors and colleagues who contributed to this research, especially Dr. Saeid Ghavami, Dr. zahra salehi, and Dr. Stevan Pecic. This experience has been incredibly enriching, teaching me valuable lessons about collaboration and teamwork. Looking forward to further discussions and collaborations in the future! #ColorectalCancer #Research #Teamwork #Gratitude #CancerResearch #UPR #TherapeuticTargets

🧬 The Latest Product Launches in the Omics sector 🧬 🧬 Bio-Rad Laboratories launches the ddPlex ESR1 Mutation Detection Kit, a highly sensitive digital PCR assay for translational research, therapy selection, and disease monitoring. Detects seven ESR1 mutations with exceptional sensitivity and same-day results. 🧬 QIAGEN introduces the QiAcuity dPCR PanCancer Kits for EGFR and BRAF mutations and the QiaSeq Targeted RNA-seq Panel for T-cell receptors, enabling precise cancer monitoring and immune repertoire characterization. 🧬 Element Biosciences unveils Aviti24, an instrument for next-gen sequencing and multiomic profiling, offering comprehensive analysis of DNA, RNA, proteins, and cell structure in under 24 hours. 🧬 Takara Bio USA, Inc. presents the Shasta Single-Cell System, an automated platform for biomarker discovery in oncology research, enabling whole-genome DNA amplification and total RNA-seq. 🧬 Bruker Canopy Biosciences CellScape Imaging Chamber enhances spatial multiplexing, allowing simultaneous staining of large tissue sections for increased throughput and flexibility. 🧬 Mission Bio: Sample Multiplexing for Tapestri: Mission Bio introduces sample multiplexing for its Tapestri single-cell DNA and protein analysis platform, streamlining workflows and accelerating genomic research. 🧬 Nonacus launches Galeas Tumor, a comprehensive genomic profiling test using next-gen sequencing, offering insights into cancer genetics and personalized medicine. 🧬 LGC Clinical Diagnostics releases Seraseq cfDNA NIPT Reference Materials for accurate noninvasive prenatal testing, supporting fetal trisomy 21 and microdeletion 22q11 syndromes. #genomics #research #biotech #innovation #pcr #ngs #cancer #oncology #biomarkers #precisionmedicine #digitalpcr #sequencing #singlecell #diagnostics #rnaseq #lifesciences #healthcare #precisionhealth